ES2116447T3 - Una composicion farmaceutica que contiene un sistema definido de lipidos. - Google Patents
Una composicion farmaceutica que contiene un sistema definido de lipidos.Info
- Publication number
- ES2116447T3 ES2116447T3 ES93908233T ES93908233T ES2116447T3 ES 2116447 T3 ES2116447 T3 ES 2116447T3 ES 93908233 T ES93908233 T ES 93908233T ES 93908233 T ES93908233 T ES 93908233T ES 2116447 T3 ES2116447 T3 ES 2116447T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- composition containing
- lipid system
- lipid
- defined lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN SISTEMA LIPIDO DEFINIDO DE AL MENOS DOS COMPONENTES LIPIDOS DONDE AL MENOS UNO DE LOS COMPONENTES LIPIDOS ES ANFIFATICO O POLAR Y OTRO ES NO POLAR EN DONDE EL COMPUESTO FARMACEUTICAMENTE ACTIVO ES UNA HEPARINA O UN FRAGMENTO DE LA MISMA. EN LAS COMPOSICIONES TAMBIEN SE INCLUYE UN SOLVENTE QUE CONTIENE AGUA EN UNA CANTIDAD TAL QUE HAYA PARTICULAS DE LIPIDOS DISCRETAS PRESENTES Y DICHAS COMPOSICIONES SE PUEDEN ADAPTAR A VARIAS FORMAS DE ADMINISTRACION TALES COMO RECTAL, ORAL, BUCAL, TRANSDERMICA, ETC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9200951A SE9200951D0 (sv) | 1992-03-27 | 1992-03-27 | Pharmaceutical composition containing a defined lipid system |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2116447T3 true ES2116447T3 (es) | 1998-07-16 |
Family
ID=20385757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93908233T Expired - Lifetime ES2116447T3 (es) | 1992-03-27 | 1993-03-26 | Una composicion farmaceutica que contiene un sistema definido de lipidos. |
Country Status (23)
Country | Link |
---|---|
US (1) | US5626869A (es) |
EP (1) | EP0591492B1 (es) |
JP (1) | JP3577312B2 (es) |
KR (1) | KR100243921B1 (es) |
AT (1) | ATE165971T1 (es) |
AU (1) | AU3912493A (es) |
CA (1) | CA2102494C (es) |
CZ (1) | CZ285672B6 (es) |
DE (1) | DE69318503T2 (es) |
DK (1) | DK0591492T3 (es) |
ES (1) | ES2116447T3 (es) |
FI (1) | FI110842B (es) |
HU (1) | HU219240B (es) |
IL (1) | IL105017A (es) |
MX (1) | MX9301716A (es) |
NO (1) | NO305537B1 (es) |
NZ (1) | NZ251488A (es) |
PL (1) | PL172896B1 (es) |
RU (1) | RU2128505C1 (es) |
SE (1) | SE9200951D0 (es) |
SK (1) | SK280494B6 (es) |
WO (1) | WO1993019737A1 (es) |
ZA (1) | ZA931470B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639469A (en) * | 1994-06-15 | 1997-06-17 | Minnesota Mining And Manufacturing Company | Transmucosal delivery system |
DE4447287C1 (de) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
US6001820A (en) * | 1995-03-31 | 1999-12-14 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5744457A (en) * | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
KR100314496B1 (ko) | 1998-05-28 | 2001-11-22 | 윤동진 | 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도 |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
EP1140021B1 (en) | 1998-12-23 | 2004-08-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
WO2001010411A2 (de) * | 1999-08-06 | 2001-02-15 | Max-Delbrück-Centrum für Molekulare Medizin | Implantierbares wirkstoffdepot |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
FR2803202B1 (fr) * | 2000-01-03 | 2004-04-16 | Capsulis | Compositions pharmaceutiques destinees a une adminstration par voie orale |
SE0000730D0 (sv) * | 2000-03-06 | 2000-03-06 | Scotia Holdings Plc | Lipid carrier |
US6761901B1 (en) | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
DE10026699A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage |
US6689760B1 (en) | 2000-07-10 | 2004-02-10 | Enzrel Inc. | Anti-mycobacterial compositions |
US6455073B1 (en) | 2000-07-10 | 2002-09-24 | Enzrel, Inc. | Covalent microparticle-drug conjugates for biological targeting |
US20020142304A1 (en) * | 2001-03-09 | 2002-10-03 | Anderson Daniel G. | Uses and methods of making microarrays of polymeric biomaterials |
US9308220B2 (en) * | 2001-12-11 | 2016-04-12 | Cosmo Technologies Limited | Pharmaceutical compositions for the oral administration of heparin or derivatives thereof |
EP1474108A2 (en) * | 2002-01-09 | 2004-11-10 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
SE0201922D0 (sv) | 2002-06-20 | 2002-06-20 | Ltp Lipid Technologies Provide | Koagulationshindrande komposition (Anticoagulant Composition) |
US6702850B1 (en) | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
US20070172517A1 (en) * | 2003-09-17 | 2007-07-26 | Ben-Sasson Shmuel A | Compositions capable of facilitation penetration across a biological barrier |
CA2611944A1 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
US20100021538A1 (en) * | 2008-02-29 | 2010-01-28 | Youngro Byun | Pharmaceutical compositions containing heparin derivatives |
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
ES2734973T3 (es) | 2009-12-01 | 2019-12-13 | Translate Bio Inc | Administración de ARNm para el aumento de proteínas y enzimas en enfermedades genéticas humanas |
JP6109574B2 (ja) | 2009-12-18 | 2017-04-05 | カタラン、フランス、バインハイム、ソシエテ、アノニムCatalent France Beinheim Sa | 合成オリゴサッカリドを含有する医薬経口剤形 |
EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
CA2898184A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
WO2014134403A2 (en) | 2013-03-01 | 2014-09-04 | Vivonics, Inc. | Aptamers that bind cd271 |
IL290953B2 (en) | 2013-03-14 | 2024-01-01 | Ethris Gmbh | CFTR mRNA Assemblies and Related Methods and Uses |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
MX2016005237A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa. |
EP3060257B1 (en) | 2013-10-22 | 2021-02-24 | Translate Bio, Inc. | Lipid formulations for delivery of messenger rna |
EP3060258A1 (en) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
CN117402871A (zh) | 2014-04-25 | 2024-01-16 | 川斯勒佰尔公司 | 信使rna的纯化方法 |
CN107002094A (zh) | 2014-05-30 | 2017-08-01 | 斯坦福大学托管董事会 | 用于治疗潜伏病毒感染的组合物和方法 |
EP3148552B1 (en) | 2014-05-30 | 2019-07-31 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
NZ727281A (en) | 2014-06-24 | 2024-02-23 | Translate Bio Inc | Stereochemically enriched compositions for delivery of nucleic acids |
EP3164379A1 (en) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
EP3324999A1 (en) | 2015-05-29 | 2018-05-30 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT8219012A0 (it) * | 1982-01-06 | 1982-01-06 | Ausonia Farma Srl | Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche. |
SE8206744D0 (sv) * | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | Preparat for kontrollerad avgivning av substanser |
JPS607934A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
JPH0753661B2 (ja) * | 1984-03-08 | 1995-06-07 | フアレス フアーマスーチカル リサーチ エヌブイ | プロ―リポソーム組成物及びリポソームの水性分散物を作る方法 |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
IE59067B1 (en) * | 1985-04-02 | 1993-12-15 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
JPH0751496B2 (ja) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
SE8603812D0 (sv) * | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
ATE115403T1 (de) * | 1987-01-27 | 1994-12-15 | Vestar Inc | Aus phospholipiden bestehende darreichungsform für wasserunlösliche wirksubstanzen. |
SE9003100D0 (sv) * | 1990-09-28 | 1990-09-28 | Kabivitrum Ab | Lipid formulation system |
-
1992
- 1992-03-27 SE SE9200951A patent/SE9200951D0/xx unknown
-
1993
- 1993-03-02 ZA ZA931470A patent/ZA931470B/xx unknown
- 1993-03-11 IL IL10501793A patent/IL105017A/en not_active IP Right Cessation
- 1993-03-26 KR KR1019930703632A patent/KR100243921B1/ko not_active IP Right Cessation
- 1993-03-26 DE DE69318503T patent/DE69318503T2/de not_active Expired - Fee Related
- 1993-03-26 EP EP93908233A patent/EP0591492B1/en not_active Expired - Lifetime
- 1993-03-26 NZ NZ251488A patent/NZ251488A/en not_active IP Right Cessation
- 1993-03-26 RU RU93058379A patent/RU2128505C1/ru not_active IP Right Cessation
- 1993-03-26 SK SK1322-93A patent/SK280494B6/sk unknown
- 1993-03-26 AU AU39124/93A patent/AU3912493A/en not_active Abandoned
- 1993-03-26 PL PL93301465A patent/PL172896B1/pl not_active IP Right Cessation
- 1993-03-26 CA CA002102494A patent/CA2102494C/en not_active Expired - Fee Related
- 1993-03-26 CZ CZ932477A patent/CZ285672B6/cs not_active IP Right Cessation
- 1993-03-26 AT AT93908233T patent/ATE165971T1/de not_active IP Right Cessation
- 1993-03-26 WO PCT/SE1993/000258 patent/WO1993019737A1/en active IP Right Grant
- 1993-03-26 HU HU9303357A patent/HU219240B/hu not_active IP Right Cessation
- 1993-03-26 ES ES93908233T patent/ES2116447T3/es not_active Expired - Lifetime
- 1993-03-26 JP JP51736193A patent/JP3577312B2/ja not_active Expired - Fee Related
- 1993-03-26 DK DK93908233T patent/DK0591492T3/da active
- 1993-03-26 MX MX9301716A patent/MX9301716A/es not_active IP Right Cessation
- 1993-11-26 FI FI935273A patent/FI110842B/fi active
- 1993-11-26 NO NO934284A patent/NO305537B1/no unknown
-
1995
- 1995-06-29 US US08/497,381 patent/US5626869A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
SE9200951D0 (sv) | 1992-03-27 |
DK0591492T3 (da) | 1999-02-15 |
DE69318503T2 (de) | 1998-11-05 |
ATE165971T1 (de) | 1998-05-15 |
HUT70405A (en) | 1995-10-30 |
CZ285672B6 (cs) | 1999-10-13 |
SK132293A3 (en) | 1994-07-06 |
CZ247793A3 (en) | 1994-07-13 |
DE69318503D1 (de) | 1998-06-18 |
EP0591492B1 (en) | 1998-05-13 |
NZ251488A (en) | 1996-03-26 |
HU219240B (en) | 2001-03-28 |
FI935273A (fi) | 1993-11-26 |
CA2102494C (en) | 2008-03-18 |
RU2128505C1 (ru) | 1999-04-10 |
EP0591492A1 (en) | 1994-04-13 |
CA2102494A1 (en) | 1993-09-28 |
ZA931470B (en) | 1993-09-23 |
US5626869A (en) | 1997-05-06 |
NO934284D0 (no) | 1993-11-26 |
FI110842B (fi) | 2003-04-15 |
FI935273A0 (fi) | 1993-11-26 |
IL105017A0 (en) | 1993-07-08 |
NO305537B1 (no) | 1999-06-21 |
JP3577312B2 (ja) | 2004-10-13 |
JPH06508155A (ja) | 1994-09-14 |
MX9301716A (es) | 1994-01-31 |
WO1993019737A1 (en) | 1993-10-14 |
HU9303357D0 (en) | 1994-03-28 |
SK280494B6 (sk) | 2000-03-13 |
AU3912493A (en) | 1993-11-08 |
KR100243921B1 (ko) | 2000-03-02 |
NO934284L (no) | 1993-11-26 |
IL105017A (en) | 1999-12-22 |
PL172896B1 (pl) | 1997-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2116447T3 (es) | Una composicion farmaceutica que contiene un sistema definido de lipidos. | |
RU93058379A (ru) | Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение | |
PT100963A (pt) | Composicoes farmaceuticas para aplicacao topica de elevada penetracao atraves da pele que compreendem certos polimeros nao-ionicos especificos | |
YU7296A (sh) | Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida | |
FI973828A0 (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
IT1255258B (it) | Composizioni farmaceutiche per l'applicazione per via nasale. | |
BR9810495A (pt) | Composição farmacêutica | |
DK0902789T3 (da) | Androstenderivater | |
ATE356608T1 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 | |
IT1212778B (it) | Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene. | |
TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
KR950007857A (ko) | 경구투여용 라파마이신 제제 | |
MA22343A1 (fr) | Compositions type massepain, contenant du psyllium | |
SE9403389D0 (sv) | Pharmaceutical composition containing derivattves of sex hormones | |
SE9403137D0 (sv) | Derivatives of carbohydrates and compositions containing them | |
YU7196A (sh) | Farmaceutska formulacija koja sadrži kombinaciju foskarneta i jednog protivzapaljenskog glukokortikoida | |
IT1270976B (it) | Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica, loro uso e composizioni farmaceutiche che li contengono | |
MX9204141A (es) | Derivados de cetal ciclicos y composicion farmaceutica que los contiene. | |
KR960021043A (ko) | 스코폴레틴을 포함하는 b형 간염 치료제 | |
KR960021046A (ko) | 카페익산을 포함하는 b형 간염 치료제 | |
ITMI920214A1 (it) | Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina | |
MX9604984A (es) | Composiciones farmaceuticas a base de derivados de la clase de los taxanos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 591492 Country of ref document: ES |